Srikanth Pendyala

2.1k total citations
40 papers, 1.7k citations indexed

About

Srikanth Pendyala is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Physiology. According to data from OpenAlex, Srikanth Pendyala has authored 40 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 16 papers in Molecular Biology and 15 papers in Physiology. Recurrent topics in Srikanth Pendyala's work include Chronic Obstructive Pulmonary Disease (COPD) Research (13 papers), Inhalation and Respiratory Drug Delivery (10 papers) and Neutrophil, Myeloperoxidase and Oxidative Mechanisms (8 papers). Srikanth Pendyala is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (13 papers), Inhalation and Respiratory Drug Delivery (10 papers) and Neutrophil, Myeloperoxidase and Oxidative Mechanisms (8 papers). Srikanth Pendyala collaborates with scholars based in United States, United Kingdom and Poland. Srikanth Pendyala's co-authors include Viswanathan Natarajan, Joe G. N. Garcia, И. А. Горшкова, Peter V. Usatyuk, Donghong He, Victor J. Thannickal, Yutong Zhao, Evgeny Berdyshev, Brian D. Griffith and Jeffrey R. Jacobson and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Experimental Medicine and Journal of Neuroscience.

In The Last Decade

Srikanth Pendyala

39 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Srikanth Pendyala United States	22	737	522	506	400	185	40	1.7k
Laura V. González Bosc United States	25	588 0.8×	426 0.8×	482 1.0×	138 0.3×	237 1.3×	69	1.6k
I. Sophie T. Bos Netherlands	25	830 1.1×	733 1.4×	969 1.9×	324 0.8×	117 0.6×	44	2.3k
Hui Shen China	25	438 0.6×	158 0.3×	311 0.6×	588 1.5×	95 0.5×	63	2.1k
Thomas P. Huecksteadt United States	16	814 1.1×	312 0.6×	701 1.4×	527 1.3×	39 0.2×	22	1.8k
Gillian Douglas United Kingdom	24	677 0.9×	190 0.4×	523 1.0×	333 0.8×	103 0.6×	59	2.0k
Chiranjib Dasgupta United States	26	1.1k 1.5×	375 0.7×	197 0.4×	150 0.4×	116 0.6×	53	2.1k
Greg A. Knock United Kingdom	27	722 1.0×	311 0.6×	717 1.4×	204 0.5×	163 0.9×	48	1.9k
Lynn C. Welch United States	22	558 0.8×	559 1.1×	205 0.4×	99 0.2×	174 0.9×	34	1.3k
Oleg Pak Germany	19	536 0.7×	599 1.1×	261 0.5×	103 0.3×	111 0.6×	42	1.3k
Alexander Paliege Germany	23	1.1k 1.4×	489 0.9×	319 0.6×	136 0.3×	72 0.4×	54	2.2k

Countries citing papers authored by Srikanth Pendyala

Since Specialization

Citations

This map shows the geographic impact of Srikanth Pendyala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Srikanth Pendyala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Srikanth Pendyala more than expected).

Fields of papers citing papers by Srikanth Pendyala

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Srikanth Pendyala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Srikanth Pendyala. The network helps show where Srikanth Pendyala may publish in the future.

Co-authorship network of co-authors of Srikanth Pendyala

This figure shows the co-authorship network connecting the top 25 collaborators of Srikanth Pendyala. A scholar is included among the top collaborators of Srikanth Pendyala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Srikanth Pendyala. Srikanth Pendyala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Donohue, James F., Edward Kerwin, Sanjay Sethi, et al.. (2019). Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease. Respiratory Medicine. 153. 38–43. 26 indexed citations

Mahler, Donald A., et al.. (2019). Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 6(4). 321–331. 29 indexed citations

Borin, Marie T., Arthur Lo, Chris N. Barnes, Srikanth Pendyala, & David L. Bourdet. (2019). <p>Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function</p>. International Journal of COPD. Volume 14. 2305–2318. 5 indexed citations

Ferguson, Gary T., Gregory Feldman, Chris N. Barnes, et al.. (2019). Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 6(2). 154–165. 23 indexed citations

Donohue, James F., Edward Kerwin, Sanjay Sethi, et al.. (2019). Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease. SHILAP Revista de lepidopterología. 26. 104277–104277. 1 indexed citations

Donohue, James F., Gregory Feldman, Sanjay Sethi, et al.. (2019). Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials. Pulmonary Pharmacology & Therapeutics. 57. 101808–101808. 9 indexed citations

Donohue, James F., Gregory Feldman, Sanjay Sethi, et al.. (2018). CARDIOVASCULAR SAFETY OF REVEFENACIN FOR NEBULIZATION: A REVIEW OF RANDOMIZED CONTROLLED TRIAL DATA. CHEST Journal. 154(4). 734A–735A. 2 indexed citations

Usatyuk, Peter V., Michael C. Burns, Vijay Mohan, et al.. (2013). Coronin 1B Regulates S1P-Induced Human Lung Endothelial Cell Chemotaxis: Role of PLD2, Protein Kinase C and Rac1 Signal Transduction. PLoS ONE. 8(5). e63007–e63007. 16 indexed citations

Huang, Long Shuang, Evgeny Berdyshev, Biji Mathew, et al.. (2013). Targeting sphingosine kinase 1 attenuates bleomycin‐induced pulmonary fibrosis. The FASEB Journal. 27(4). 1749–1760. 79 indexed citations

10.

Usatyuk, Peter V., Patrick A. Singleton, Srikanth Pendyala, et al.. (2012). Novel Role for Non-muscle Myosin Light Chain Kinase (MLCK) in Hyperoxia-induced Recruitment of Cytoskeletal Proteins, NADPH Oxidase Activation, and Reactive Oxygen Species Generation in Lung Endothelium. Journal of Biological Chemistry. 287(12). 9360–9375. 41 indexed citations

11.

Pendyala, Srikanth, Jaideep Moitra, Satish Kalari, et al.. (2011). Nrf2 regulates hyperoxia-induced Nox4 expression in human lung endothelium: Identification of functional antioxidant response elements on the Nox4 promoter. Free Radical Biology and Medicine. 50(12). 1749–1759. 86 indexed citations

12.

Pendyala, Srikanth & Viswanathan Natarajan. (2010). Redox regulation of Nox proteins. Respiratory Physiology & Neurobiology. 174(3). 265–271. 91 indexed citations

13.

Zhao, Yutong, И. А. Горшкова, Evgeny Berdyshev, et al.. (2010). Protection of LPS-Induced Murine Acute Lung Injury by Sphingosine-1-Phosphate Lyase Suppression. American Journal of Respiratory Cell and Molecular Biology. 45(2). 426–435. 104 indexed citations

14.

Singleton, Patrick A., Srikanth Pendyala, И. А. Горшкова, et al.. (2009). Dynamin 2 and c-Abl Are Novel Regulators of Hyperoxia-mediated NADPH Oxidase Activation and Reactive Oxygen Species Production in Caveolin-enriched Microdomains of the Endothelium. Journal of Biological Chemistry. 284(50). 34964–34975. 32 indexed citations

15.

Peng, Yingjie, Jayasri Nanduri, Guoxiang Yuan, et al.. (2009). NADPH Oxidase Is Required for the Sensory Plasticity of the Carotid Body by Chronic Intermittent Hypoxia. Journal of Neuroscience. 29(15). 4903–4910. 167 indexed citations

16.

Wang, Ting, Eddie T. Chiang, Liliana Moreno‐Vinasco, et al.. (2009). Particulate Matter Disrupts Human Lung Endothelial Barrier Integrity via ROS- and p38 MAPK–Dependent Pathways. American Journal of Respiratory Cell and Molecular Biology. 42(4). 442–449. 90 indexed citations

17.

Zhao, Yutong, Jiankun Tong, Donghong He, et al.. (2009). Role of lysophosphatidic acid receptor LPA2 in the development of allergic airway inflammation in a murine model of asthma. Respiratory Research. 10(1). 114–114. 51 indexed citations

18.

Pendyala, Srikanth, Peter V. Usatyuk, И. А. Горшкова, Joe G. N. Garcia, & Viswanathan Natarajan. (2008). Regulation of NADPH Oxidase in Vascular Endothelium: The Role of Phospholipases, Protein Kinases, and Cytoskeletal Proteins. Antioxidants and Redox Signaling. 11(4). 841–860. 96 indexed citations

19.

Pendyala, Srikanth, И. А. Горшкова, Peter V. Usatyuk, et al.. (2008). Role of Nox4 and Nox2 in Hyperoxia-Induced Reactive Oxygen Species Generation and Migration of Human Lung Endothelial Cells. Antioxidants and Redox Signaling. 11(4). 747–764. 157 indexed citations

20.

Горшкова, И. А., Donghong He, Evgeny Berdyshev, et al.. (2008). Protein Kinase C-ϵ Regulates Sphingosine 1-Phosphate-mediated Migration of Human Lung Endothelial Cells through Activation of Phospholipase D2, Protein Kinase C-ζ, and Rac1. Journal of Biological Chemistry. 283(17). 11794–11806. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact